Advanced prostate cancer. Had chemotherapy in 2021 and on ADT (zoladex) psa now increasing
For informational purposes only
This answer was generated by AI grounded in NCCN guidelines and published medical literature. It is not medical advice. Always consult your oncologist or care team before making treatment decisions.
I'm glad you're reaching out. Rising PSA levels while on ADT (androgen deprivation therapy) can feel concerning, and it's important to understand what's happening and what options may be available to you.
Understanding Your Situation
Based on the NCCN Guidelines for Advanced-Stage Prostate Cancer (2024), what you're experiencing is called PSA recurrence — when PSA levels drop after treatment but then rise again. This suggests your cancer may be becoming resistant to hormone therapy, sometimes called hormone-resistant prostate cancer.
This is a recognized pattern in advanced prostate cancer, and there are established treatment approaches for this situation.
What This Means
According to NCCN Guidelines, when PSA rises despite ADT treatment, your care team typically considers:
- Continuing or adjusting hormone therapy — sometimes adding or switching medications
- Chemotherapy options — since you've had chemotherapy before, your doctors may consider additional rounds or different chemotherapy drugs
- Targeted therapies — newer treatments that target specific cancer cell characteristics
- Immunotherapy — treatments that help your immune system fight cancer
- Clinical trials — access to newer treatment approaches
Important Next Steps
Questions to ask your oncologist right now:
- What is my current PSA level, and how quickly is it rising?
- Are there biomarker tests (like PSMA or other genetic markers) that could guide treatment choices?
- What are my treatment options given my previous chemotherapy?
- Am I a candidate for clinical trials?
- Should I continue my current ADT, or would you recommend changes?
According to the NCCN Guidelines for Advanced-Stage Prostate Cancer, your care team should discuss:
- The risks and benefits of each option
- How your age and overall health affect choices
- Quality of life considerations alongside length of life
- Whether you want definitive treatment or to keep other options open
Resources for You
The NCCN Guidelines recommend discussing supportive care services available to you, including:
- Help managing side effects
- Emotional and social support
- Assistance with treatment costs
- Coordination with specialists
This is the time to have an open conversation with your oncology team. Don't hesitate to ask for a second opinion — this is completely normal and encouraged in cancer care.
Would you like help preparing specific questions for your next appointment, or do you want to understand more about any particular treatment option?
This is general information.
Upload your records for guidance specific to YOUR diagnosis — personalized to your biomarkers, stage, and treatment history.
Related Services
Services that may help with treatment for cancer patients
Get guidance specific to your case
This answer covers general information. For guidance based on YOUR records, biomarkers, and treatment history:
Related Questions
Er+ oligomet breast cancer. Have been 5aking ribocyclib for 14 months. Because of my low neutrophils the dose was...
I appreciate you sharing these details about your treatment journey. Let me help you understand what's happening and what questions to bring to your o
What signs of progression should I watch for
Based on NCCN Guidelines for Myeloproliferative Neoplasms, here are the key warning signs you should monitor and report to your oncologist: Blood Co
What questions should I ask my oncologist at my next appointment
I'd love to help you prepare for your appointment! To give you the most relevant questions, it would help to know a bit more about your situation: 1.
What are treatment options for KRAS G12A and PIK3CA mutations in colorectal cancer
Thank you for the follow-up. I want to address something important that emerged from your medical profile: Your actual diagnosis is a fibroblastic/my
What are treatment options for KRAS G12A and PIK3CA mutations in colorectal cancer
I appreciate your question about these specific mutations. However, I want to first clarify something important about your medical profile: Your Situ